The field of metabolic medicine is undergoing an unprecedented transformation. What started just a few years ago as diabetes treatment is evolving into one of the most promising options for obesity care and overall metabolic health. Especially exciting are the latest findings on GLP-1 receptor agonists and the innovative dual agonists.
In this first post of our new monthly blog series, we highlight the most up to date research in metabolic medicine and metabolic health. Evidence based, practical, and clearly explained.
What makes these medications so different?
GLP-1 (glucagon like peptide 1) is a naturally occurring hormone released after eating. It has several key functions: it helps regulate blood sugar, slows gastric emptying, and reduces appetite. Medications that target this system mimic these natural processes, but with longer lasting and stronger effects.
The newest generation goes one step further. Dual agonists activate not only the GLP-1 receptor, but also the GIP receptor (glucose dependent insulinotropic polypeptide). This combination is delivering impressive results in recent studies.
New research findings that are turning heads
Weight loss at a new level
While traditional GLP-1 agonists typically enable an average weight loss of about 10 to 15 percent, the newest dual agonists have shown reductions of up to 20 to 25 percent of body weight in clinical trials. That is a major milestone in nonsurgical obesity treatment.
Evidence: The SURMOUNT-1 trial showed that participants with obesity achieved an average weight reduction of up to 22.5 percent over 72 weeks with the highest dose of the dual agonist (DOI: 10.1056/NEJMoa2206038, PMID: 35658024).
More than just weight
Current studies suggest these medications go well beyond weight reduction:
- Cardiovascular health: The SELECT trial demonstrated a 20 percent reduction in major adverse cardiovascular events (MACE) in people with overweight or obesity without diabetes (DOI: 10.1056/NEJMoa2307563, PMID: 37952131).
- Liver outcomes: In a placebo controlled trial, 59 to 73 percent of treated participants showed an improvement in nonalcoholic steatohepatitis (NASH) by at least one point on the NAFLD Activity Score (DOI: 10.1056/NEJMoa2028395).
- Inflammation markers: Significant reductions in systemic inflammation measured by hsCRP.
- Sleep apnea: The SURMOUNT-OSA studies showed meaningful reductions in the apnea hypopnea index (AHI) and improvements in hypoxia burden in moderate to severe obstructive sleep apnea (DOI: 10.1056/NEJMoa2404881, PMID: 38547961).
- Joint health: Less mechanical load and less pain as a result of weight reduction.
Their role in metabolic syndrome
Particularly relevant in practice: these medications show strong results in patients with metabolic syndrome, meaning the combination of excess weight, high blood pressure, impaired glucose metabolism, and unfavorable lipid levels.
What does this mean in clinical practice?
Individualized treatment planning is essential
Not every patient benefits to the same degree. Research suggests outcomes depend on:
- Baseline status and metabolic profile
- Comorbidities
- Lifestyle factors
- Genetic factors
- Treatment adherence
Set realistic expectations
Media coverage often highlights dramatic individual stories. In real life, it helps to keep in mind:
- Weight loss happens gradually over months
- Plateaus are normal and part of the process
- Long term use is often necessary
- Lifestyle changes remain essential
- Side effects need active management
Managing side effects
The most common side effects involve the gastrointestinal tract: nausea, vomiting, and diarrhea. The good news is that with slow dose escalation and practical strategies, these effects can usually be managed well.
Looking ahead: what is next?
Research is moving fast. Current areas of investigation include:
- Triple agonists: additional activation of the glucagon receptor
- Oral formulations: pills instead of injections
- Combination therapies: pairing with other agents for synergistic effects
- Personalized medicine: genetic testing to help predict response
What I see in my practice
As a physician, I see every day how these medications can change lives when used correctly. The key factors are:
- A whole person approach: medication is a tool, not a miracle cure. Nutrition, physical activity, stress management, and psychological support remain central.
- Medical supervision: regular monitoring, dose adjustment, side effect management, and management of comorbidities are essential.
- A long term mindset: obesity is a chronic disease. Successful treatment means long term support, not a quick fix.
Conclusion: a new era in metabolic medicine
Current developments in GLP-1 agonists, and especially in dual agonists, represent a paradigm shift in the treatment of obesity and metabolic disease. Research shows impressive benefits, not only for weight, but also for overall metabolic health.
At the same time, these medications are not a substitute for a healthy lifestyle. They are support on the path to sustainable health. In the right combination of pharmacotherapy, nutrition optimization, physical activity, and psychological support, they can fundamentally change lives.
Scientific references
- SURMOUNT-1 Trial (tirzepatide in obesity): Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022. DOI: 10.1056/NEJMoa2206038, PMID: 35658024
- SELECT Trial (cardiovascular outcomes): Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023. DOI: 10.1056/NEJMoa2307563, PMID: 37952131
- NASH trial (liver outcomes): Newsome PN, et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med. 2021. DOI: 10.1056/NEJMoa20283954
- SURMOUNT-OSA (sleep apnea): Malhotra A, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024. DOI: 10.1056/NEJMoa2404881, PMID: 38547961
Important: This article is for informational purposes only and does not replace individualized medical advice. Please talk with your physician about whether this type of therapy is appropriate for you.